Endotoxic hypoglycaemia has an important role in the survival rates of septic patients. Previous studies have demonstrated that hypothalamic AMP-activated protein kinase (hyp-AMPK) activity is sufficient to modulate glucose homeostasis. However, the role of hyp-AMPK in hypoglycaemia associated with endotoxemia is unknown. The aims of this study were to examine hyp-AMPK dephosphorylation in lipopolysaccharide (LPS)-treated mice and to determine whether pharmacological hyp-AMPK activation could reduce the effects of endotoxemia on blood glucose levels. LPS-treated mice showed reduced food intake, diminished basal glycemia, increased serum TNF-a and IL-1b levels and increased hypothalamic p-TAK and TLR4/MyD88 association. These effects were accompanied by hyp-AMPK/ACC dephosphorylation. LPS-treated mice also showed diminished liver expression of PEPCK/G6Pase, reduction in p-FOXO1, p-AMPK, p-STAT3 and p-JNK level and glucose production. Pharmacological hyp-AMPK activation blocked the effects of LPS on the hyp-AMPK phosphorylation, liver PEPCK expression and glucose production. Furthermore, the effects of LPS were TLR4-dependent because hyp-AMPK phosphorylation, liver PEPCK expression and fasting glycemia were not affected in TLR4-mutant mice. These results suggest that hyp-AMPK activity may be an important pharmacological target to control glucose homeostasis during endotoxemia.
Introduction
Blood glucose levels must be maintained at homeostasis for survival. During periods of food deprivation, the liver is the major source of glucose production. Hepatic glycogenolysis and gluconeogenesis release glucose into the bloodstream to provide for extrahepatic tissues. These pathways are under control of glucagon, corticosterone, cathecolamines and insulin. Increased hepatic gluconeogenesis is related to hyperglycemia (Saltiel, 2001 ). The expression of phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis, is stimulated by glucagon and corticosterone. In contrast, increase in blood insulin levels inhibits its expression (Pilkis and Granner, 1992) . These hormones modulate the activation of transcription factors that contribute to gluconeogenic gene expression in the liver such as the forkhead box O 1 (FOXO1) , Jun N-terminal kinase (JNK) (Chanda et al., 2011) , AMP-activated protein kinase (AMPK) and signal transducer and activator of transcription 3 (STAT3) (Inoue et al., 2004; Koo et al., 2005) .
The role of hypothalamic nuclei in the control of glucose homeostasis has been investigated. Studies have demonstrated that the neuronal malonyl-CoA pathway modulates glucose production and food intake Gao et al., 2007; Lam et al., 2005a,b; Minokoshi et al., 2004; Obici et al., 2003; Obici et al., 2002a,b; Pocai et al., 2005a,b; Ross et al., 2008) . MalonylCoA biosynthesis is under control of acetyl-CoA carboxylase (ACC), which is phosphorylated and inactivated by AMPK (Hardie and Pan, 2002; Saha and Ruderman, 2003) .
The importance of AMPK and the ACC pathway in glucose homeostasis has been widely demonstrated. Hypothalamic AMPK is inhibited by hormonal signals and nutrient availability. The pharmacological inhibition of hypothalamic AMPK lowers glucose production, impairing the counter-regulatory response and peripheral insulin signalling Stoppa et al., 2008) . In contrast, AMPK may be activated by neuroglucopenia, hypoglycaemia and food deprivation Han et al., 2005; Minokoshi et al., 2004) . Intracerebroventricular (ICV) administration of AICAR, an AMPK activator, or the infusion of the constitutively active form of AMPK negates the ability of hypothalamic glucose/lactate-sensing mechanisms to decrease glucose production (Lam et al., 2005a,b; Yang et al., 2010) . Interestingly, similar to leptin, the intraperitoneal administration of lipopolysaccharide (LPS), a ligand of Toll-like receptor 4 (TLR4), increased the phosphorylation of STAT3 in the hypothalamus and liver (Hosoi et al., 2004; Yamawaki et al., 2010) .
In animal models of diabetes and obesity, gluconeogenesis is increased, contributing to hyperglycemia (De Souza et al., 2010; Friedman et al., 1997; Herzig et al., 2001; Melo et al., 2011) , while in streptozotocin-induced diabetic rats, hypothalamic AMPK phosphorylation and activity are increased . Yang and colleagues (Yang et al., 2010) have shown that knocking down hypothalamic AMPK activity results in significant suppression of glucose production. In addition, in experimental models of endotoxemia, the exposure to LPS, leads to diminished hepatic glucose production, hypoglycaemia and inhibition of PEPCK expression (Chichelnitskiy et al., 2009; Hill and McCallum, 1991; Vogel et al., 1991) .
Endotoxic hypoglycaemia is a critical factor in the survival rates of septic patients (Krinsley and Grover, 2007; Waeschle et al., 2008) . Recently, Feingold and colleagues showed that LPS and TNF-a reduced the PEPCK expression in liver and fat, but LPS-induced decrease in PEPCK expression did not occur in TLR4-deficient animals or TNF receptor/IL-1 receptor knockout mice (Feingold et al., 2012) . In addition, Steinberg and colleagues showed that TNFalpha signaling through TNF receptor (TNFR) 1 suppresses AMPK activity via transcriptional upregulation of protein phosphatase 2C (PP2C) (Steinberg et al., 2006) .
Here we show that central action of LPS is important to impaired liver glucose production. In parallel, we demonstrate that hypothalamic AMPK activation prevents hypoglycaemia after LPS treatment.
Material and methods

Ethical approval
This study was conducted in strict accordance with the recommendations of the COBEA (Brazilian College of Animal Experimentation) guidelines, which was approved by the Ethical Committee for Animal Use (ECAU) (ID protocol: 2517-1) of the Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Animals and surgical procedures
Male C3H/HeJ or C3H/HeN mice (loss-of-function mutation for TLR4 and its respective control) and Swiss male mice (10 wk old, 25-30 g) were taken from the University's central breeding colony and maintained in polypropylene cages in a room at 24 ± 1°C with lights on from 6:00 to 18:00 h and fed diets and water ad libitum. When necessary, the mice were chronically instrumented with an ICV cannula and kept under controlled temperature and light-dark conditions in individual metabolic cages. Surgery was performed under anesthesia, and all efforts were made to minimise animal suffering. In brief, the animals were anesthetised with 50 mg/kg ketamine and 5 mg/kg diazepam (IP) and positioned onto a Stoelting stereotaxic apparatus after the loss of cornea and foot reflexes. A stainless steel 23-gauge guided cannula with an indwelling 30-gauge obturator was stereotaxically implanted into the lateral cerebral ventricle at pre-established coordinates, anteroposterior, 0.34 mm from bregma; lateral, 1.0 mm; and vertical, 2.2 mm, according to a previously reported technique (Michelotto et al., 2002) . The cannulas were considered correctly positioned as confirmed by dipsogenic response elicited after injection of 2 lL 10 À6 -M angiotensin II (McKinley et al., 2001) . After tests for cannula function and position, mice were randomly assigned to one of the experimental groups. For treatment with 5-amino-1-b-D-ribofuranosyl-imidazole-4-carboxamide (AICAR), 3 lL of bolus injection of 2 mmol/L was injected into the lateral ventricle. LPS (1 mg/kg) was administered intraperitoneally in fasted mice. After 4 h, the hypothalamus and liver were extracted and rapidly dissected on an ice-cold plate. Samples were snap-frozen in liquid nitrogen and stored at À80°C.
Measurements of food intake
Mice were housed individually in metabolic cages before experimentation for acclimatization. The mice were fasted overnight (14 h) and then injected with vehicle (saline, IP) or LPS (1 mg/kg, IP). Thirty minutes after the injection, animals were given a preweighted amount of food, and food intake was recorded 24 h after refeeding.
Glucose (IPGTT) and pyruvate (IPPTT) tolerance tests
The intraperitoneal glucose tolerance test (IPGTT) was performed after overnight fasting. After collection of an unchallenged sample (time 0), 25% glucose (2.0 g/kg) was administered into the peritoneal cavity. Tail blood samples were collected at different intervals for determination of glucose concentration. For intraperitoneal pyruvate test (IPPTT), fasted mice (overnight, 14 h) were injected with 15% sodium pyruvate (0.5 g/kg). Blood samples were collected from the tail vein immediately before and at various time points (0-120 min) after the administration of pyruvate loading dose measure blood glucose.
Tissue extraction and immunoblotting
Tissue samples were obtained and homogenised in freshly prepared ice cold buffer (1% Triton X 100, 100 mM Tris, pH 7.4, 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM PMSF, and 0.01 mg aprotinin/mL). The insoluble material was removed by centrifugation (10,000 X g) for 25 min at 4°C. The protein concentration in the supernatant was determined by the Bradford dye-binding method. The supernatant was resuspended in Laemmli sample buffer and boiled for 5 min before separation by SDS-PAGE using a miniature slab gel apparatus (Bio Rad, Richmond, CA, USA). Electrotransfer of proteins from the gel to nitrocellulose was performed for 90 min at 120 V (constant). The nitrocellulose blots were probed with specific antibodies. The PEPCK (sc-32879), glucose-6-phosphatase (G6Pase) (sc-25840), the total JNK (sc-571) and phospho-JNK (sc-6254), TLR-4 (sc-10741), transforming growth factor b-activated kinase 1 (TAK1) (sc-292804) and phospho-TAK1 (sc-130219), STAT3 (sc-408) and phospho-STAT3 (sc-8001-R), and b-actin (sc-47778) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The total AMPK (#2603) and phospho-AMPK (#2535), total ACC (#3676) and phospho-ACC (#3661) and FOXO1 (#9454) and p-FOXO1/2/3 (#2599) antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Subsequently, the blots were incubated with HRP-conjugated secondary antibodies (KPL, Gaithersburg, MD, USA). The results were visualised by autoradiograph with preflashed Kodak XAR film. Band intensities were quantified by optical densitometry of developed autoradiographs (Scion Image software, ScionCorp), and the intensities of the bands were normalised to those of total protein or the loading control b-actin.
Real-time PCR analysis
Hepatic total RNA was extracted using Trizol reagent (Invitrogen Corporation, CA, USA) according to the manufacturer's recommendations. Total RNA was rendered genomic DNA-free by digestion with RNAse-free DNAse (RQ1, Promega, Madison, WI, USA). Reverse-transcription was performed using total RNA from hepatic samples. Intron-skipping primers for PEPCK and G6Pase mRNAs were obtained (Applied Biosystems, CA, USA). Real-time PCR analysis of gene expression was performed in an ABI Prism 7500 sequence detection system (Applied Biosystems). The optimal cDNA and primer concentrations as well as the maximum efficiency of amplification were obtained through five-point, twofold dilution curve analysis for each gene. Each PCR contained 20 ng of reverse-transcribed RNA and was run according to the manufacturer's recommendation using the TaqMan PCR Master Mix (Applied Biosystems). Target mRNA expression was normalised to b-actin expression and expressed as a relative value using the comparative threshold cycle (Ct) method (2ÀDDCt) according to the manufacturer's instructions.
Biochemical and hormonal measurements
Blood glucose was determined using a glucometer. Serum insulin, glucagon, and corticosterone were analysed simultaneously and measured in duplicate at all time points using a commercially available mice endocrine Linco-plex kit (Rendo-85 K, Linco Research, St. Charles, MO, USA). The levels serum of TNF-a and IL1b were analysed using a commercially available kit from Biolegend Ò . All blood samples were collected from animal decapitation.
Data presentation and statistical analysis
All numerical results are expressed as mean ± SE of the indicated number of experiments. Blot results are presented as direct band comparisons in autoradiographs and quantified by densitometry using the Scion Image software (ScionCorp). Student's t-tests of unpaired samples and variance analysis (ANOVA) for multiple comparisons were used. Post-hoc test (Tukey) was employed for determining a significance level of p < 0.05.
Results
Initially, we evaluated the effects of different doses of LPS (0.1, 0.5 and 1 mg/kg) on the basal glycemia. The blood samples were collected 4 h after LPS injection. This time was chosen based on a previous study (Yamawaki et al., 2010) . In Fig. 1A , only LPS-treated mice (1.0 mg/kg) presented basal glycemia that was significantly reduced compared with control (45 and 80 mg/dL, respectively). As expected, the overnight food intake (24 h) was significantly reduced compared with control (Fig. 1B) , although the animals were previously fasted (6 h). Both serum TNF-a (Fig. 1C) and IL-1b levels ( Fig. 1D) were analysed, but only TNF-a levels increased significantly after treatment with LPS compared with control (639 ± 118 and 36 ± 9 pg/ml, respectively).
Next, we measured the effects of LPS on hypothalamic AMPK and ACC phosphorylation. As demonstrated in Fig. 2A , LPS treatment reduced (45%) the hypothalamic AMPK phosphorylation compared with control mice. The hypothalamic ACC phosphorylation was also reduced (75%) in LPS-treated mice (Fig. 2B) . Because ACC is a target protein of AMPK, this result suggests that mice treated with LPS present reduced AMPK activity. LPS had no effect on total hypothalamic AMPK and ACC expression.
To evaluate the activation of inflammatory pathways in the hypothalamus from mice treated with LPS (1.0 mg/kg), we initially measured the expression of TLR4 and the phosphorylation of TAK1. As shown in Fig. 3A , TLR4 protein was detected in the hypothalamus, and its expression was not modified by LPS treatment. Consistent with TLR4 pathway activation, LPS-treated mice showed higher levels of p-TAK1 (2.6-fold) and association of TLR4/MyD88 (4.8-fold) (Fig. 3B and C, respectively) than control mice. We also evaluated the hypothalamic STAT3 phosphorylation in fasted mice 240 min after injection of LPS. Hypothalamic STAT3 phosphorylation was higher in LPS-treated mice than in control (1.6-fold) (Fig. 3D) .
Next, we evaluated the ability of liver to produce glucose in fasted mice previously treated with LPS. Initially, blood glucose was measured 30 min after pyruvate challenge. Blood glucose 30 min after pyruvate administration increased from 102 ± 5.2 mg/dL to 183 ± 10.7 mg/dL in control mice, whereas in mice previously treated with LPS, glucose levels increased from 102 ± 9.9 mg/dL to 144 ± 6 mg/dL, approximately 50% lower than control mice (Fig. 4A ). In addition, we evaluated the glucose tolerance in control and LPS mice. As shown in Fig. 4B , the tolerance to glucose demonstrated by area under curve was significantly improved in LPS-treated mice compared with control mice. Hepatic expression of PEPCK and G6Pase were quantified by western blotting. LPS-treated mice showed lower hepatic G6Pase (Fig. 4C) and PEPCK (4D) protein (1.5-fold and 1.8-fold, respectively) than control mice. PEPCK mRNA expression was also significantly reduced by LPS (Fig. 4E) (3.1-fold) , but no difference was observed in G6Pase mRNA expression (data not shown).
PEPCK expression is controlled at the transcriptional level by hormones including insulin, glucagon and glucocorticoids. As demonstrated in the Table 1 , serum insulin and glucagon were higher in LPS (376.7 ± 82.9 and 47.5 ± 13.2 pM, respectively) than control mice (150.3 ± 7.3 and 16.02 ± 5.1 pM, respectively). Among the complex network of transcription factors that may modulate gluconeogenic gene expression in liver, FoxO1, JNK and STAT3 are important. To examine the phosphorylation of these proteins in LPS-treated mice, we performed western blotting of liver tissues 4 h after treatment. As observed in Fig. 5 , the phosphorylation status of STAT3, FOXO1, and JNK proteins in the liver was increased by LPS (2.5-fold, 3.5-fold and 1.7-fold, respectively) compared with the control mice (Fig. 5A-C) . These results were consistent with the diminished expression of PEPCK and G6Pase in this tissue. LPS did not change total protein levels. Moreover, liver AMPK phosphorylation was significantly reduced (1.4-fold) after LPS challenge compared with control mice (Fig. 5D) .
Next, we evaluated whether pharmacological activation of hypothalamic AMPK could inhibit the effects of LPS on hepatic PEP-CK expression. According to Figs. 2A and 6A , hypothalamic AMPK phosphorylation was reduced by LPS administration (1.3-fold). However, previous administration of AICAR (0.2 mmol, ICV) blocked the effects of LPS on hypothalamic AMPK phosphorylation (Fig. 6A ). Hepatic expression of PEPCK was analysed by western blotting and real time PCR (Fig. 6B and C) . LPS did not modify hepatic PEPCK expression in mice previously treated with AICAR. In addition, glycemia 240 min after LPS challenge was improved by previous administration of AICAR (Fig. 6D) . Interestingly, the previous injection of AICAR did not prevent the increase in serum levels of TNF-a and IL-1b in LPS-treated mice (Table 1) . Finally, we evaluated hypothalamic AMPK phosphorylation and hepatic PEPCK expression in control (C3H/HeN) and TLR4 loss-offunction mutation (C3H/HeJ) mice. As shown in Fig. 7A , hypothalamic AMPK phosphorylation was significantly reduced by LPS administration in C3H/HeN mice (1.6-fold) compared with saline-treated C3H/HeN mice. In C3H/HeJ mice, LPS administration was unable to dephosphorylate AMPK. In addition, hepatic PEPCK expression in C3H/HeN mice was partially reduced by LPS, whereas in C3H/HeJ mice, LPS had no effect (Fig. 7B) . Interestingly, the basal PEPCK expression was higher in C3H/HeJ than in C3H/HeN mice.
Discussion
The maintenance of glucose homeostasis is crucial for mammalian survival and critical to the central nervous system (CNS). CNS has redundant molecular mechanisms to control the release of hormones and glucose production in the liver. In the hypothalamus, the activation of AMPK results in liver glucose production (Lam et al., 2005a,b; Minokoshi et al., 2004) . In contrast, liver glucose production is diminished when AMPK is inhibited Stoppa et al., 2008) . The ventromedial nucleus of the hypothalamus (VMH) has been implicated in the control of energy homeostasis (Lopez et al., 2010) . Here, we show that intraperitoneal administration of LPS results in the reduction of glycemia and hypothalamic AMPK phosphorylation. ACC, a protein target of AMPK (Saha and Ruderman, 2003) , also presented reduced phosphorylation after LPS challenge. The AMPK/ACC/malonyl CoA pathway in the hypothalamus has been implicated in the regulation of hepatic glucose production McCrimmon et al., 2004) and reduction of food intake in mice Minokoshi et al., 2004) . In addition, VMH neurons have been associated to control of peripheral energy homeostasis (Kim et al., 2012 McCrimmon et al., 2004) .
According to Lang and colleagues (Lang et al., 1993) , the increase in glucose uptake in the diaphragm, spleen, liver and lungs may contribute to hypoglycaemia in LPS-treated rats. This effect could be due to macrophages augmentation of their cellular glucose uptake facilitated by increased GLUT1 expression and mediated by TNF-a (Gamelli et al., 1996) . Acute exposure to LPS increases serum TNF-a and IL-1b and can cause hypoglycaemia (Vogel et al., 1991) . Although glucose uptake was not evaluated in LPS-treated mice, they showed high levels of serum cytokines (TNF-a and IL-1b), reduced food intake and lowered activity of the AMPK/ACC pathway. These effects were accompanied by hypoglycaemia and reduction in liver PEPCK and G6Pase expression, modifications that are commonly observed in models of acute illness or acute exposition of LPS (Abram et al., 2000 ; Borges et al., 2011; Hart, 1988) and in other models (Chichelnitskiy et al., 2009; Feingold et al., 2012; Hill and McCallum, 1991; Maitra et al., 1999) . SIRT1 overexpression (Xue et al., 2012) and binding of high mobility group box 1 protein (HMGB1) to LKB1, inhibit the anti-inflammatory effects of AMPK (Tadie et al., 2012) . These findings strengthen the hypothesis that the central control of food intake, glucose production and the inflammatory response to LPS has a common pathway.
Furthermore, Mastronardi and colleagues showed that injection of LPS in conscious rats increased plasma leptin within 2 h (Mastronardi et al., 2000) . Similar results were observed in mice (Finck et al., 1998) . It is known that in vivo administration of leptin decreases hypothalamic AMPK activity. Therefore, it is possible that plasma leptin may be responsible for inducing hypothalamic AMPK dephosphorylation in our study.
TLR4 protein is important in mediating the effects of LPS on hepatic metabolism (Feingold et al., 2012) and CNS (Olson and Miller, 2004) . TLR4 protein could be the connection between hypothalamic AMPK dephosphorylation and hypoglycaemia promoted by LPS, as suggested by two different groups (Soraya et al., 2012; Tadie et al., 2012) . LPS-treated mice did not modify TLR4 expression in the hypothalamus, but TAK1 phosphorylation and TLR4/ MYD88 association were increased, suggesting TLR4 pathway activation (Yamawaki et al., 2010) . Interestingly, hypothalamic STAT3 phosphorylation in LPS-treated mice was also increased. Hypothalamic STAT3 is a common signalling protein in the hypothalamus for modulating food intake and glucose production, mainly from glycogenolysis by leptin and insulin (Borges et al., 2011; Carvalheira et al., 2005; Pocai et al., 2005a,b) . However, our results showed the reduction of PEPCK expression, an enzyme that did not participate in glycogenolysis, suggesting that the reduction in glycemia was provoked by lowered de novo synthesis of glucose.
The role of hypothalamic TLR4 protein in LPS-mediated glucose production was also investigated in C3H/HeJ mice with loss-offunction mutation for TLR4. In LPS-treated C3H/HeJ mice, hypothalamic AMPK phosphorylation, liver PEPCK expression and basal glucose (240 min after LPS challenge) were not altered. In contrast, all parameters were reduced by LPS treatment in control mice. Although, the mutation in C3H/HeJ mice is not tissue-specific and thus the inflammatory response to LPS is diminished compared with control mice, these results reinforce the role of TLR4 pathway in hypothalamic AMPK dephosphorylation and consequently in the control of glucose homeostasis.
Insulin and glucagon have important roles in the control of glucose homeostasis. Concurrent with the earlier studies, which found that exogenous LPS to humans and rats enhances pancreatic secretion of both insulin and glucagon (Cornell, 1985) , we found high levels of blood insulin and glucagon in LPS-treated mice. Surely, insulin can act directly on the liver and CNS to inhibit glucose production. In this sense, LPS-treated mice presented high liver p-FOXO1, p-STAT3, p-JNK and p-AMPK levels. These proteins are all related to control of genes involved in gluconeogenesis (Chanda et al., 2011; Inoue et al., 2004; Koo et al., 2005; . Specifically, FOXO1 and STAT3 were described to be activated by insulin (Inoue et al., 2006 (Inoue et al., , 2004 .
Finally, to delineate the relationship between AMPK inhibition and the reduction of liver glucose production and hypoglycaemia, we performed the pharmacological activation of hypothalamic AMPK through AICAR injection (ICV). The administration of AICAR prevented hypothalamic AMPK dephosphorylation by LPS. Concomitantly, PEPCK mRNA and protein levels in liver fragments were similar to the control group. Consistently, while LPS promoted reduction of glycemia (240 min after LPS challenge), the previous treatment with AICAR also prevented it. It is important to point that AICAR administration was performed in the lateral ventricle and some authors have shown that VMH is the main hypothalamic region related to the control of energy homeostasis (Lopez et al., 2010; McCrimmon et al., 2004 McCrimmon et al., ,2008 . It is possible that AMPK in VMH has been inhibited since selective downregulation of AMPK in this area significantly suppressed the counterregulatory response to subsequent hypoglycemia (McCrimmon et al., 2008) .
In summary, our results suggest the involvement of hypothalamic AMPK in the hypoglycaemia arising from endotoxemia. Under physiological conditions, AMPK helps orchestrate hepatic metabolism and pancreas activity; however, during endotoxemia, AMPK is dephosphorylated, leading to hormonal and metabolic disturbances and eventually hypoglycaemia. Overall, hypothalamic AMPK activity could be a target for controlling hypoglycaemia frequently present under septic conditions. 
